BOSTON--(BUSINESS WIRE)--NovaDigm Therapeutics, a company developing innovative immuno-therapeutics and preventative vaccines for fungal and bacterial infections, today announced the initiation of a ...
BOSTON--(BUSINESS WIRE)--NovaDigm Therapeutics, a company developing innovative immunotherapeutics and preventative vaccines for fungal and bacterial infections, today announced awards totaling $6 ...
NovaDigm Therapeutics a company developing innovative vaccines for fungal and bacterial infections today announced that it has closed a $14M Series B financing. Participating investors included new ...
Whereas most vaccines under development are designed to protect against one kind of pathogen, NovaDigm Therapeutics thinks a vaccine it’s developing could protect against certain fungal and bacterial ...
GRAND FORKS, N.D., Jun 10, 2014 (BUSINESS WIRE) -- NovaDigm Therapeutics , a company developing innovative vaccines for fungal and bacterial infections, today announced that it has acquired the rights ...
NovaDigm Therapeutics, a company developing innovative immuno-therapeutics and preventative vaccines for fungal and bacterial infections, announced the initiation of a phase 2a study evaluating NDV-3A ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
NovaDigm Therapeutics Raises $14M Series B to Support Phase 2 Trial of NDV-3 Vaccine Against Candida
GRAND FORKS, N.D.--(BUSINESS WIRE)--NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that it has closed a $14M Series B financing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback